Aptinyx Inc (APTX)

Etorro trading 970x250
Aptinyx Inc (APTX) Logo

About Aptinyx Inc

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson’s disease cognitive impairment. The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois. Address: 909 Davis Street, Evanston, IL, United States, 60201

Aptinyx Inc News and around…

Latest news about Aptinyx Inc (APTX) common stock and company :

Aptinyx to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
18 Nov, 2021 FinancialContent

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held November 29, 2021 through December 2, 2021.

Notable Aptinyx Insider Makes $190K Buy
16 Nov, 2021 Yahoo! Finance

Robert Hombach, Insider at Aptinyx (NASDAQ:APTX), made a large insider buy on November 12, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Hombach purchased 80,000 shares of Aptinyx at at a price of $2.40. The total transaction amounted to $192,000. Following the transaction, Hombach now owns 229,100 shares of Aptinyx, worth $556,713. Aptinyx shares are trading up 5.19% at $2.43 at the time of this writing on Tu

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
16 Nov, 2021 FinancialContent

Gainers Kezar Life Sciences (NASDAQ:KZR) stock rose 48.27% to $12.47 during Tuesday's pre-market session. The market ...

Aptinyx Inc. (APTX) Q3 2021 Earnings Call Transcript
10 Nov, 2021 FinancialContent

APTX earnings call for the period ending September 30, 2021.

Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights
09 Nov, 2021 FinancialContent

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2021 and provided key business updates across the company’s clinical-stage pipeline of novel NMDA receptor modulators.

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
09 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For ...

Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
27 Oct, 2021 FinancialContent

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment in the company’s ongoing Phase 2b study of NYX-2925 for the treatment of painful diabetic peripheral neuropathy (DPN). Patients recently enrolled in the study are completing the 12-week treatment period and 30-day safety follow-up period. The company expects to report results from the study in early to mid 2Q 2022.

Aptinyx to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
25 Oct, 2021 FinancialContent

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 9, 2021 at 5:00 p.m. ET to report third quarter 2021 financial results and discuss recent business highlights.

12 Health Care Stocks Moving In Friday's Pre-Market Session
22 Oct, 2021 FinancialContent

Gainers Nutriband (NASDAQ:NTRB) shares rose 15.52% to $6.72 during Friday's pre-market session. The market value of ...

Aptinyx Appoints Gilmore O’Neill, M.B., M.M.Sc., to Board of Directors
20 Oct, 2021 FinancialContent

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore O’Neill, M.B., M.M.Sc., to the company’s board of directors. Dr. O’Neill currently serves as chief medical officer and executive vice president of research and development at Sarepta Therapeutics.

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Aptinyx to Participate in 2021 Cantor Virtual Global Healthcare Conference
20 Sep, 2021 FinancialContent

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021 at 10:00 a.m. ET.

Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures
16 Sep, 2021 FinancialContent

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has entered into a $50 million loan facility and security agreement with K2 HealthVentures (K2HV). The funds will provide general growth capital as Aptinyx advances its late-stage clinical pipeline of novel NMDA modulators.

Aptinyx to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
31 Aug, 2021 FinancialContent

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually September 13-15, 2021.

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
19 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Aptinyx Inc. (APTX) Q2 2021 Earnings Call Transcript
11 Aug, 2021 FinancialContent

APTX earnings call for the period ending June 30, 2021.

CORRECTING and REPLACING Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights
10 Aug, 2021 FinancialContent

In the Condensed Balance Sheet, last line should read:

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
10 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

28 Stocks Moving in Tuesday's Pre-Market Session
10 Aug, 2021 FinancialContent

Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares rose 38.6% to $66.88 in pre-market trading after the company ...

Earnings Scheduled For August 10, 2021
10 Aug, 2021 FinancialContent

Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its ...

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
08 Aug, 2021 FinancialContent

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

Aptinyx to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference
03 Aug, 2021 FinancialContent

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the “Brains of the Operation - Novel Approaches in Neuro” panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10 at 12:00 p.m. ET.

Aptinyx to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference
03 Aug, 2021 Yahoo! Finance

EVANSTON, Ill., August 03, 2021--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the "Brains of the Operation - Novel Approaches in Neuro" panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10 at 12:00 p.m. ET.

We're Not Very Worried About Aptinyx's (NASDAQ:APTX) Cash Burn Rate
29 Jul, 2021 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Aptinyx to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021
26 Jul, 2021 FinancialContent

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, August 10, 2021 at 5:00 p.m. ET to report second quarter 2021 financial results and discuss recent business highlights.

Aptinyx to Participate in William Blair Biotech Focus Conference 2021
12 Jul, 2021 FinancialContent

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the Updates in Neuropysch panel discussion at the William Blair Biotech Focus Conference on Thursday, July 15 at 12:00 p.m. ET.

Aptinyx Stock Looks Promising If You’re Willing to Be Patient
12 Jul, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips When you're shopping for ground-floor biotech opportunities, it pays to be patient and diligent. APTX stock is looking good here. The post Aptinyx Stock Looks Promising If You’re Willing to Be Patient appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn’t matter if you have $500 in savings or $5 million. Do this now.

Aptinyx Inc (APTX) is a NASDAQ Common Stock listed in , ,

970x250